

Special Issue

Molecular Diagnosis and Treatment of Leukemia

Message from the Guest Editor

In the last several decades the field of leukemia has seen important advancements in the diagnosis, classification, and treatment of these patients. One of the first cornerstones in this regard is represented by the discovery that the BCR-ABL fusion is frequently present in chronic myeloid leukemia, and that it can be targeted with single-agent non-chemotherapy represented by imatinib. Since then, this approach has been extended to other leukemia, such as acute myeloid leukemia, acute lymphoblastic leukemia, myeloproliferative neoplasms, and others. At present, most hospitals offer mutational analysis for genes like FLT3, JAK2, CALR, and MPL, to name a few. This has advanced in other hospitals with the existence of comprehensive gene panels that can better assess the prognosis of each patient. Thus, the current Special Issue will be taking papers assessing the use of a variety of molecular markers in leukemia biology, diagnosis, prognosis, and treatment.

Guest Editor

Dr. Ancuta Jurj

Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania

Deadline for manuscript submissions

closed (31 December 2020)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/49604

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).